Skip to main content

Alexion Value Stock - Dividend - Research Selection

Alexion Pharmaceuticals

ISIN: US0153511094, WKN: 899527

Market price date: 28.07.2021
Market price: 182,50 USD


Alexion Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 10-02-2021
Cash flow
Net operating cash flow 3.002.900.000
Capital Expenditures -106.700.000
Free cash flow 2.896.199.936
Balance sheet
Total Equity 11.651.200.000
Liabilities & Shareholders equity 18.103.000.000
Income statement
Net income 603.400.000
Eps (diluted) 2,720
Diluted shares outstanding 444.000.000
Net sales/revenue 6.069.900.000

Fundamental ratios calculated on: 28-07-2021

Ratios
Key figures 28-07-2021
Cash flow
P/C 26,98
   
P/FC 27,98
Balance sheet
ROI3,33
ROE64,36
Income statement
P/E67,10
Div. Yield0,00%
P/B6,96
P/S13,35


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolALXN
Market Capitalization81.029.996.544,00 USD
CountryUnited States
IndicesMSCI World Index
SectorsBiotechnology
Raw Data SourceUS GAAP in Millionen USD
Stock Split2011-05-24,2.0000/1.0000; 2011-05-23,2.0000/1.0000; 2008-08-26,2.0000/1.0000; 2008-08-25,2.0000/1.0000
Internetwww.alexion.com


Description of the company

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. On February 7, 2012, it acquired Enobia Pharma Corp. (Enobia). On February 8, 2011, it acquired patents and assets from Orphatec Pharmaceuticals GmbH (Orphatec). On January 28, 2011, it acquired Taligen Therapeutics, Inc. (Taligen). It acquired Asfotase alfa in February 2012.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.alexion.com


NEWS